California State Teachers Retirement System boosted its position in shares of Arrowhead Research Corp. (NASDAQ:ARWR) by 0.7% during the second quarter, Holdings Channel reports. The institutional investor owned 126,906 shares of the company’s stock after buying an additional 852 shares during the period. California State Teachers Retirement System owned approximately 0.21% of Arrowhead Research Corp. worth $675,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp increased its position in Arrowhead Research Corp. by 0.3% in the first quarter. State Street Corp now owns 944,860 shares of the company’s stock worth $4,551,000 after buying an additional 3,053 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Arrowhead Research Corp. by 8.3% in the first quarter. Geode Capital Management LLC now owns 408,065 shares of the company’s stock worth $1,966,000 after buying an additional 31,293 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Arrowhead Research Corp. by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 290,559 shares of the company’s stock worth $1,547,000 after buying an additional 19,376 shares in the last quarter. Finally, Falcon Point Capital LLC increased its stake in shares of Arrowhead Research Corp. by 12.5% in the second quarter. Falcon Point Capital LLC now owns 49,147 shares of the company’s stock worth $261,000 after buying an additional 5,458 shares in the last quarter. Hedge funds and other institutional investors own 33.92% of the company’s stock.
Arrowhead Research Corp. (NASDAQ:ARWR) traded up 1.39% during mid-day trading on Tuesday, reaching $7.28. The company’s stock had a trading volume of 562,711 shares. The firm’s 50 day moving average price is $7.11 and its 200 day moving average price is $6.01. The stock’s market cap is $442.26 million. Arrowhead Research Corp. has a 12-month low of $3.07 and a 12-month high of $8.22.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.05. The business earned $39.58 million during the quarter, compared to analysts’ expectations of $0.05 million. Arrowhead Research Corp. had a negative return on equity of 100.50% and a negative net margin of 48,980.81%. The business’s revenue was down 68.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.27) earnings per share. On average, equities analysts predict that Arrowhead Research Corp. will post ($1.31) earnings per share for the current year.
A number of analysts recently issued reports on ARWR shares. Cantor Fitzgerald started coverage on Arrowhead Research Corp. in a research report on Wednesday, August 17th. They issued a “buy” rating and a $15.00 price target for the company. Chardan Capital set a $10.00 price target on Arrowhead Research Corp. and gave the stock a “buy” rating in a research report on Thursday, September 29th. William Blair started coverage on Arrowhead Research Corp. in a research report on Friday, August 19th. They issued an “outperform” rating for the company. Finally, Piper Jaffray Cos. lowered their price target on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $10.11.
In other news, CFO Kenneth Allen Myszkowski sold 13,100 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $8.00, for a total value of $104,800.00. Following the completion of the sale, the chief financial officer now directly owns 128,789 shares in the company, valued at $1,030,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.90% of the stock is owned by insiders.
Arrowhead Research Corp. Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Research Corp. (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.